Literature DB >> 1086423

High dose methotrexate therapy of solid tumors: observations relating to clinical toxicity.

W H Isacoff, C M Townsend, F R Eiber, T Forster, D L Morton, J B Block.   

Abstract

In clinical studies performed during 111 infusions of high dose methotrexate (MTX) we have evolved a clinical and laboratory protocol which permits such therapy without prohibitive risk to the patient. The plasma MTX data obtained indicate that pharmacokinetic disposition is dose related during these infusions and that such data are useful in identifying patients at risk from serious toxicity.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1086423     DOI: 10.1002/mpo.2950020313

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  11 in total

1.  [High-dose methotrexate therapy in osteogenic sarcoma: plasma pharmakokinetics to predict toxicity (author's transl)].

Authors:  G E Janka; H Wiesner; F Bidlingmaier; R J Haas
Journal:  Klin Wochenschr       Date:  1979-04-17

2.  Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients.

Authors:  W E Evans; C B Pratt; R H Taylor; L F Barker; W R Crom
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

3.  High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients.

Authors:  Laila Holmboe; Anders M Andersen; Lars Mørkrid; Lars Slørdal; Kirsten Sundby Hall
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

4.  Therapeutic drug monitoring.

Authors:  D K Oxley; C L Fischer
Journal:  West J Med       Date:  1978-01

Review 5.  Dose-dependent pharmacokinetics and cancer chemotherapy.

Authors:  G Powis; M M Ames; J S Kovach
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

6.  Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate.

Authors:  Jason N Barreto; Kristen T Peterson; Erin F Barreto; Kristin C Mara; Ross A Dierkhising; Nelson Leung; Thomas E Witzig; Carrie A Thompson
Journal:  Support Care Cancer       Date:  2021-03-04       Impact factor: 3.603

7.  Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.

Authors:  Marc Ghannoum; Darren M Roberts; David S Goldfarb; Jesper Heldrup; Kurt Anseeuw; Tais F Galvao; Thomas D Nolin; Robert S Hoffman; Valery Lavergne; Paul Meyers; Sophie Gosselin; Tudor Botnaru; Karine Mardini; David M Wood
Journal:  Clin J Am Soc Nephrol       Date:  2022-03-02       Impact factor: 10.614

8.  Mathematical modeling -- guide to high-dose methotrexate infusion therapy.

Authors:  S D Reich
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 9.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics of commonly used anticancer drugs.

Authors:  F M Balis; J S Holcenberg; W A Bleyer
Journal:  Clin Pharmacokinet       Date:  1983 May-Jun       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.